 CAMBRIDGE, Mass., Nov. 25, 2020 GLOBE NEWSWIRE -- Trillium Therapeutics Inc. NASDAQTSX: TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology ASH Annual Meeting, which is being held virtually from December 5-8, 2020. 